Omzo vs Ro.co: Compounded Injectables vs Wegovy Pill Choice
Omzo vs Ro.co matters most if you need to choose between compounded weekly injectables and an FDA-approved oral GLP-1 option. Quick verdict: Omzo focuses on clinician-guided compounded semaglutide starting at $179, while Ro.co provides access to the FDA-approved Wegovy pill with a $39 get-started entry for patients eligible after clinician review.
Explore Omzo clinician-guided plans
How the services differ at a glance: Omzo vs Ro.co
This comparison highlights the most distinctive differences based only on supplied facts: medication type and regulatory status, starting cost and price structure, route of administration and patient preference, and clinician review and prescribing pathway. Both platforms use licensed clinicians who determine medical appropriateness.
1. Medication type and regulatory status
Omzo connects patients with licensed U.S. providers for a Compounded Medication Program that supplies compounded semaglutide and tirzepatide. Compounded medications are prepared by state-licensed sterile compounding pharmacies but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Omzo also notes providers may write prescriptions for branded medications, but Omzo does not sell or ship branded products.
Ro.co is the only mainstream platform on this list that offers access to the Wegovy pill, described as the first and only FDA-approved oral GLP-1 weight loss medication on the captured page. Ro.co emphasizes that finished, FDA-approved medications differ from compounded alternatives in regulatory assurance. Treatment is available only when a licensed clinician determines it is medically appropriate.
2. Starting price and pricing entry point
Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as captured. Ro.co advertises a get-started online price of $39. Ro.co also states that ongoing branded medication pricing depends on the treatment plan and medication prescribed and that branded medications carry higher costs than compounded alternatives.
3. Route of administration and patient preference
Omzo offers compounded semaglutide and tirzepatide as one weekly injection, which may suit patients comfortable with injectables. Ro.co offers the Wegovy pill as an oral GLP-1 option, which is significant for injection-averse patients who prefer an oral, FDA-approved product. The Wegovy pill removes the injection barrier for those who avoid injectables.
4. Clinician review, eligibility, and program scope
Both platforms require licensed clinician review. Omzo states clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make final prescribing decisions. Omzo warns that Omzo is not a medical practice and the website assessment does not create a doctor-patient relationship. Ro.co also requires a licensed clinician to determine medical appropriateness before treatment is available. Ro.co notes pricing is disclosed before you complete the consultation.
Side-by-side comparison table
| Criteria | Omzo | Ro.co |
|---|---|---|
| Medication type | Compounded semaglutide and tirzepatide | Wegovy pill (FDA-approved oral GLP-1) |
| Regulatory status | Compounded drugs not FDA-approved | Finished FDA-approved medication |
| Starting price | Semaglutide starting at $179 | Get started online for just $39 |
| Administration | One weekly injection (compounded) | Oral pill, no injections |
| Clinician requirement | Licensed U.S. providers determine eligibility | Licensed clinician determines medical appropriateness |
| Prescription handling | Providers may write prescriptions for branded meds; Omzo does not sell or ship branded medications | Offers access to branded Wegovy pill; pricing disclosed before consultation |
What each provider emphasizes
Omzo emphasizes clinician-guided plans reviewed by licensed U.S. providers, compounded semaglutide and tirzepatide with fast, discreet delivery, and that compounded medications are produced in FDA-registered facilities but are not FDA-approved. Omzo warns that results vary and eligibility, pricing, and state coverage may change.
Compare Omzo medication options
Ro.co emphasizes access to the Wegovy pill as an FDA-approved oral GLP-1, an entry point of $39 to get started online, no hidden fees, and that ongoing branded medication pricing depends on the plan and medication prescribed. Ro.co positions the oral option as beneficial for injection-averse patients and notes branded medications cost more than compounded alternatives.
Start with Ro.co for oral GLP-1
Safety, regulatory notes, and limitations
Both sources include a regulatory note that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Omzo explicitly states its compounded drugs are not FDA-approved and that providers make the final determination on prescriptions. Ro.co highlights that FDA-approved finished products carry stronger regulatory assurance compared with compounded options.
Choose Omzo if…
You want clinician-guided access to compounded semaglutide or tirzepatide with medication costs starting at $179 and accept that compounded medications are not FDA-approved. Confirm eligibility, total cost, renewal terms, and state availability before enrollment.
Choose Ro.co if…
You prefer an FDA-approved oral GLP-1 option and an injection-free route, want a $39 online entry point, and are prepared for ongoing branded medication pricing that depends on your prescribed plan.